Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m (→Also known as) |
m (→Also known as) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tucidinostat NCI Drug Dictionary]: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tucidinostat NCI Drug Dictionary]: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Adult T-cell leukemia-lymphoma]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *2021-06-23: Newly indicated for the treatment of relapsed or refractory [[adult T-cell leukemia-lymphoma]]. | ||
| + | *2021-11-25: New indication for the treatment of relapsed or refractory [[peripheral T-cell lymphoma]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' CS-055, HBI-8000 |
*'''Generic name:''' tucidinostat | *'''Generic name:''' tucidinostat | ||
| − | *'''Brand name:''' Epidaza | + | *'''Brand name:''' Epidaza, Hiyasta |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 17: | Line 20: | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| + | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
| + | [[Category:PMDA approved in 2021]] | ||
Latest revision as of 19:27, 13 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells.
Diseases for which it is used
History of changes in PMDA indication
- 2021-06-23: Newly indicated for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
- 2021-11-25: New indication for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Also known as
- Code names: CS-055, HBI-8000
- Generic name: tucidinostat
- Brand name: Epidaza, Hiyasta